

Programme

AIR 2017, the 7th Advancing ILD Research Educational Meeting

Barcelona, Spain 17–18 November 2017

Meeting Co-Chairs: Athol Wells, Maria Molina-Molina

Scientific Committee:

Carlo Albera, Katerina Antoniou, Jürgen Behr, Elisabeth Bendstrup, Vincent Cottin,
Bruno Crestani, Jim Egan, Thomas Geiser, Andreas Günther, Michael Kreuter,
Maria Molina-Molina, Venerino Poletti, Luca Richeldi, Carlos Robalo Cordeiro,
Anne-Marie Russell, Simon Walsh, Athol Wells, Marlies Wijssenbeek

Programme

Friday 17th November

13:00–13:05 Introduction and overview of Roche commitment to respiratory
Jean-Marc Haeusler TBD

13:05–13:10 Chairs' welcome and introduction
Athol Wells, Maria Molina-Molina

13:10–13:15 iPad demonstration
Agency

Session 1: **ILD: A year in review** *Chairs: Antje Prasse, Athol Wells*

13:15–13:35 What's new in pathophysiology of fibrotic lung disease?
Thomas Geiser

13:35–13:55 Have we gained new insights into the mechanism of action of antifibrotic drugs?
Gisli Jenkins

13:55–14:15 What's new in ILD imaging?
Simon Walsh

Session 2: **Early diagnosis and treatment of IPF** *Chair: Toby Maher*

14:15–14:35 IPF diagnostic criteria: Imminent changes
Athol Wells

14:35–14:55 National treatment guidelines
Elisabeth Bendstrup

14:55–15:35 Debate: Should all patients with IPF be treated immediately upon diagnosis?
Patient organisation representative: Nicola Cassidy
Pro: Venerino Poletti; Con: António Morais

15:35–15:55 *Coffee break*

15:55–17:00 MDT case discussion

- Breakout session Purple
- Breakout session Blue
- Breakout session Grey

Chair clinicians: Ulrich Costabel, Martin Kolb, Martina Vašáková

Radiologists: Tomás Franquet, Nicola Sverzellati, Simon Walsh

Pathologists: Aurélie Fabre, Marianne Kambouchner TBD, Andrew Nicholson

Programme

Friday 17th November

Session 3: Real-world patient management *Chair: Carlos Robalo Cordeiro*

- 17:00–17:20 Persisting with antifibrotic treatment – what can we learn from real-world data?
Wim Wuyts
- 17:20–17:40 Quality of life in real-world IPF care
Marlies Wijzenbeek
- 17:40–18:00 Comorbidities and comedications in IPF – real-world insights
Michael Kreuter
- 18:00–18:30 Debate: Acute exacerbations and respiratory-related hospitalisation – what is more relevant for the real world?
Hospitalisation: Toby Maher; Acute exacerbations: Manuela Funke
- 18:30–18:35 *Summary and close of Day 1*
Athol Wells, Maria Molina-Molina

Programme

Saturday 18th November

08:30–08:35 Welcome back to Day 2
Athol Wells, Maria Molina-Molina

Session 4: Improving care in IPF – the patient perspective *Chair: Hilario Nunes*

08:35–09:05 Debate: Is palliative care in IPF the same as oncology?
Pro: Anne-Marie Russell; Con: Sabrina Bajwah

09:05–09:25 Strengthening the patient voice in IPF – what can we learn from PAH?
Francesco Bonella

09:25–09:45 Effective patient advocacy in IPF in Europe
EU-IPFF representative: Liam Galvin

09:45–10:05 Raising awareness of IPF as a rare disease – the Italian IPF charter
Patient organisation representative: Maria Luisa Parisi TBD

10:05–10:30 *Coffee break and group photo*

Session 5: Grand rounds in ILD *Chairs: Nazia Chaudhuri, Sergio Harari, Dominique Valeyre*

10:30–12:20 Case study reviews:

- Breakout session Purple
- Breakout session Blue
- Breakout session Grey

12:20–13:20 *Lunch*

Session 6: Combination therapy in IPF *Chairs: Carlo Albera, Diego Castillo*

13:20–13:40 Pirfenidone in combination with nintedanib
Claudia Valenzuela

13:40–14:00 Pulmonary hypertension & IPF – design of combination treatment studies
Jürgen Behr

14:00–14:20 Other combinations in IPF
Carlo Vancheri

Programme

Saturday 18th November

Session 7: Advancing ILD research – future directions
Chairs: Raphael Borie, Manuela Funke

- 14:20–14:40 Unclassifiable ILD and IPAF – diagnostic issues and treatment challenges
Vincent Cottin
- 14:40–15:00 Categorising disease subtypes: Genetic signatures of disease
Maria Molina-Molina
- 15:00–15:30 Debate: Is IPF an autoimmune disease?
Pro: Bruno Crestani; Con: Katerina Antoniou
- 15:30–15:50 ILD in rheumatological conditions
Christopher Denton TBD
- 15:50–15:55 *Concluding remarks*
Athol Wells, Maria Molina-Molina

Programme

Faculty

Athol Wells (Co-Chair)	<i>UK</i>	Antje Prasse	<i>Germany</i>
Maria Molina-Molina (Co-Chair)	<i>Spain</i>	Carlos Robalo Cordeiro	<i>Portugal</i>
Carlo Albera	<i>Italy</i>	Anne-Marie Russell	<i>UK</i>
Katerina Antoniou	<i>Greece</i>	Nicola Sverzellati	<i>Italy</i>
Sabrina Bajwah	<i>UK</i>	Claudia Valenzuela	<i>Spain</i>
Jürgen Behr	<i>Germany</i>	Dominique Valeyre	<i>France</i>
Elisabeth Bendstrup	<i>Denmark</i>	Carlo Vancheri	<i>Italy</i>
Francesco Bonella	<i>Germany</i>	Martina Vašáková	<i>Czech Republic</i>
Raphael Borie	<i>France</i>	Simon Walsh	<i>UK</i>
Nicola Cassidy	<i>Ireland</i>	Marlies Wijsenbeek	<i>Netherlands</i>
Diego Castillo	<i>Spain</i>	Wim Wuyts	<i>Belgium</i>
Nazia Chaudhuri	<i>UK</i>		
Ulrich Costabel	<i>Germany</i>		
Vincent Cottin	<i>France</i>		
Bruno Crestani	<i>France</i>		
Christopher Denton	<i>UK</i>		
Aurélie Fabre	<i>Ireland</i>		
Tomás Franquet	<i>Spain</i>		
Manuela Funke	<i>Switzerland</i>		
Liam Galvin	<i>UK</i>		
Thomas Geiser	<i>Switzerland</i>		
Sergio Harari	<i>Italy</i>		
Gisli Jenkins	<i>UK</i>		
Marianne Kambouchner	<i>France</i>		
Martin Kolb	<i>Canada</i>		
Michael Kreuter	<i>Germany</i>		
Toby Maher	<i>UK</i>		
António Morais	<i>Portugal</i>		
Andrew Nicholson	<i>UK</i>		
Hilario Nunes	<i>France</i>		
Maria Luisa Parisi	<i>Italy</i>		
Venerino Poletti	<i>Italy</i>		